Treats moderate acne vulgaris in females at least 15 years of age. ANDA 90793, held by Xiromed. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 90793 (Tri-Estarylla), held by Xiromed, was first approved by FDA on Jan 30, 2013, with 5 approved supplements and 0 published complete response letters.
Tri-Estarylla (norgestimate and ethinyl estrdiol tablets) is a combinations of norgestimate, a progestin, and ethinyl estradiol, and estrogen, indicated for use by females of reproductive potential to prevent pregnancy. Tri-Estarylla is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Estarylla should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 30, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Estarylla0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Feb 1, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 3, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 30, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters